Journal of Addiction and Dependence
2017
John Samaan
Background/Introduction: Marijuana has been used for its psychotropic effects including enhanced relaxation and perceptual alterations. However, the use of synthetic cannabis (marijuana) leads to more frequent and drastic side effects than the typical use of regular marijuana, owing to the fact that synthetic cannabis has a shorter duration and an earlier peak of action. Despite all the...
CNS & Neurological Disorders - Drug Targets
2017
Francesco P Busardò, Manuela Pellegrini, Julia Klein et al.
Delta (9)-tetrahydrocannabinol (THC) is the main psychoactive compound in cannabis and is frequently identified in blood samples from apprehended drivers suspected for driving under the influence of drugs. Changing social norms towards cannabis and higher acceptability towards the drug emphasize the need for in-depth understanding of the acute neurocognitive and psychomotor effects caused by...
December 7, 2016
C. Jeantet
Le cannabis est la drogue illégale la plus consommée actuellement en France. Le Δ9-tétrahydrocannabinol (Δ9-THC), en tant qu’excocannabinoïde, a un impact sur le système visuel via le système endocannabinoïde. Physiologiquement, parmi les deux voies majoritairement responsables de la transmission de l’information visuelle aux stades les plus précoces, la voie magnocellulaire pourrait être la...
Schizophrenia Research: Cognition
December 1, 2016
Ashley M. Schnakenberg Martin, K. Bonfils, Beshaun J. Davis et al.
Literature on the relationship of cannabis use and cognition in schizophrenia provides the paradoxical view that cannabis use is sometimes linked with less severe impairment in neurocognition. This paper explored the possibility that this is a reflection of a dose related response between lifetime cannabis use and two forms of cognition, neurocognition and metacognition, in schizophrenia. It...
Journal of Medical Toxicology
December 2016
Milana Zaurova, Robert S Hoffman, David Vlahov et al.
Synthetic cannabinoid receptor agonists (SCRAs) are heterogeneous compounds originally intended as probes of the endogenous cannabinoid system or as potential therapeutic agents. We assessed the clinical toxicity associated with recent SCRA use in a large cohort of drug overdose patients. This subgroup analysis of a large (n = 3739) drug overdose cohort study involved consecutive ED patients at...
Psychological Medicine
December 2016
Michael Bloomfield, E Mouchlianitis, C J A Morgan et al.
Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity. We tested 17 cannabis users and 17 age- and...
Translational Psychiatry
November 29, 2016
Claire Mokrysz, Tom P. Freeman, Saana M. Korkki et al.
111 citations
Preclinical research demonstrates that cannabinoids have differing effects in adolescent and adult animals. Whether these findings translate to humans has not yet been investigated. Here we believe we conducted the first study to compare the acute effects of cannabis in human adolescent (n=20; 16-17 years old) and adult (n=20; 24-28 years old) male cannabis users, in a placebo-controlled,...
November 15, 2016
Daniel G Barrus, Kristen Capogrossi, Sheryl Cates et al.
Food products containing cannabis extract (edibles) have emerged as a popular and lucrative facet of the legalized market for both recreational and medicinal cannabis. The many formulations of cannabis extracts used in edibles present a unique regulatory challenge for policy makers. Though edibles are often considered a safe, discreet, and effective means of attaining the therapeutic and/or...
Forensic Science International
November 2016
Percy Bondallaz, Bernard Favrat, Haïthem Chtioui et al.
Traffic policies show growing concerns about driving under the influence of cannabis, since cannabinoids are one of the most frequently encountered psychoactive substances in the blood of drivers who are drug-impaired and/or involved in accidents, and in the context of a legalization of medical marijuana and of recreational use. The neurobiological mechanisms underlying the effects of cannabis...
Journal of Applied Toxicology
November 2016
Rebecca L Hartman, Timothy L Brown, Gary Milavetz et al.
Although evidence suggests cannabis impairs driving, its driving-performance effects are not fully characterized. We aimed to establish cannabis' effects on driving longitudinal control (with and without alcohol, drivers' most common drug combination) relative to psychoactive ∆(9) -tetrahydrocannabinol (THC) blood concentrations. Current occasional (≥1×/last 3 months, ≤3 days per week) cannabis...